Oral Serd (selective Estrogen Receptor Degrader)

Imlunestrant

Unknown Manufacturer

Indications

Imlunestrant is recommended for ESR1-mutated metastatic breast cancer after at least one line of endocrine therapy, preferably in patients who had a prolonged response to prior CDK4/6 inhibitor therapy (per 2026 ESMO Clinical Practice Guideline for metastatic breast cancer).

Associated Conditions

3 associated conditions

metastatic breast cancer
ER-positive/HER2-negative breast cancer
ESR1-mutated breast cancer

Drug Type

oral SERD (selective estrogen receptor degrader)

Patents

One entry per invention. Patent families filed in the US, EP, WO and CN offices.

IMLUNESTRANT OR SALTS THEREOF FOR USE IN TREATING AND PREVENTING CENTRAL NERVOUS SYSTEM (CNS) METASTASES IN SUBJECTS HAVING ER+ BREAST CANCER
EP 4704841 A1Applicant: LILLY CO ELIPriority: 2023
EP
WO
2 publications

Drugs